10-Q: Sera Prognostics Reports First Quarter 2025 Results, Highlights Progress on PreTRM Test Commercialization

Sera Prognostics announces its Q1 2025 financial results, focusing on commercializing the PreTRM test and advancing its pipeline.

Summary

• Sera Prognostics reported a net loss of $8.2 million for the three months ended March 31, 2025, compared to a net loss of $8.1 million for the same period in 2024.
• Revenue for the quarter was $38 thousand.
• The company's operating expenses totaled $9.3 million, slightly higher than the $9.1 million in the prior year.
• Research and development expenses decreased by $0.3 million, while selling and marketing expenses increased by $0.2 million.
• General and administrative expenses increased by $0.3 million.
• The company completed a public offering in February 2025, raising net proceeds of $53.6 million.
• As of March 31, 2025, Sera Prognostics had cash, cash equivalents, and available-for-sale securities totaling $114.2 million.
• The company believes its cash runway is sufficient to operate through 2028 based on existing operating plans.
• Sera Prognostics is focused on commercializing its PreTRM test and developing additional biomarker tests.
• The company is actively seeking publication of full PRIME data and expects additional publications on exploratory analyses and economic benefits in the coming months.
• The first of the company's real-world evidence studies has received IRB approval and is expected to begin enrolling patients in the coming months.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company has a solid cash position and runway, it continues to operate at a loss and faces significant challenges in achieving market adoption and reimbursement for its PreTRM test.

Positives

• The company's cash runway is projected to last through 2028.
• The company completed a public offering in February 2025, raising net proceeds of $53.6 million.
• Real-world evidence studies are expected to begin enrolling patients in the coming months.
• The company is actively seeking publication of full PRIME data and expects additional publications on exploratory analyses and economic benefits in the coming months.

Negatives

• The company continues to incur net losses, with a net loss of $8.2 million reported for Q1 2025.
• Revenue for the quarter was only $38 thousand.
• The company's accumulated deficit as of March 31, 2025, was $288.0 million.

Risks

• The company's success depends on broad scientific and market acceptance of the PreTRM test and its other pipeline products and services.
• The company relies on a limited number of suppliers for some of its laboratory instruments and materials.
• The company may be subject to claims challenging the inventorship of its patents and other intellectual property.
• The company may be subject to claims that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
• The company may be adversely impacted by changes in laws and regulations, or in their application.
• The company may be subject to extensive regulatory requirements and may be required to conduct additional clinical trials prior to continuing to sell its existing tests or launching any other tests it may develop, which may increase the cost of conducting, or otherwise harm, its business.

Future Outlook

The company expects to incur significant additional operating losses and negative cash flows for the foreseeable future, primarily due to commercialization activities for the PreTRM test and research and development of other pipeline products and services. The company believes its cash runway is sufficient to operate through 2028 based on existing operating plans.

Management Comments

• We believe our cash runway is sufficient to enable us to operate through 2028 based on our existing operating plans.
• We will continue to evaluate the allocation of our resources as we focus our efforts to accelerate the market adoption of our PreTRM test and the development and launch of additional pipeline products and services.

Industry Context

The company operates in the competitive life science industry, specifically in molecular diagnostics and proteomics, where technological changes, new product introductions, and reimbursement challenges are common. The company is focused on improving maternal and neonatal health through its proprietary platform and biomarker tests.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• To compare Sera Prognostics to industry standards, we would need to analyze its revenue growth, R&D spending, and market penetration relative to companies like Myriad Genetics, Natera, and Veracyte.
• Additionally, comparing the clinical utility and cost-effectiveness of the PreTRM test to other prenatal screening methods would provide valuable context.

Legal Proceedings

• The Company is not currently a party to any material litigation or other material legal proceedings.

Related Party Transactions

• Entities affiliated with one of the Company's principal stockholders purchased Pre-Funded Warrants to purchase an aggregate of 11,250,000 shares of Class A common stock.
• One of the Company's other principal stockholders purchased an aggregate of 625,000 shares of Class A common stock in the public offering.

Stakeholder Impact

• Shareholders: Dilution from recent equity offerings, potential for long-term growth if PreTRM test gains wider adoption.
• Employees: Job security due to sufficient cash runway, potential for growth and development with new product development.
• Customers (Pregnant Women): Access to potentially valuable risk assessment for preterm birth.
• Payers: Potential for cost savings if PreTRM test reduces preterm births and associated healthcare costs.

Next Steps

• Continue to pursue contracts with private and governmental payers and health systems.
• Focus efforts to accelerate the market adoption of the PreTRM test.
• Continue the development and launch of additional pipeline products and services.
• Seek publication of full PRIME data and generate additional publications on exploratory analyses and economic benefits.
• Begin enrolling patients in the first of the company's real-world evidence studies.

Key Dates

Keywords

PreTRM test, Sera Prognostics, Financial results, Q1 2025, Commercialization, Biomarker tests, Proteomics, Bioinformatics, Maternal health, Neonatal health